Procaps Group S.A. logo

Procaps Group S.A. (PROCW)

Delisted
12 Mar 2026
NASDAQ (NMS) NASDAQ (NMS)
$
0. 02
+0
+33.7931%
$
1.96M Market Cap
8.23 P/E Ratio
- Div Yield
282,516 Volume
0 Eps
$ 0.01
Previous Close
Day Range
0.02 0.02
Year Range
0.01 0.02
Want to track PROCW and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

This company has been delisted from its primary exchange and is no longer publicly traded.
As a result, real-time price data, dividend updates, and corporate disclosures may no longer be available.

PROCW Chart

Procaps Group S.A. (PROCW) FAQ

What does "Delisted" mean?

Procaps Group S.A. has been removed from the exchange and is no longer publicly traded.

What was the last recorded dividend?

No dividend payments were recorded prior to delisting.

How long did the company pay dividends?

The company did not have a dividend payment history.

Were there any stock splits?

No stock splits were recorded prior to delisting.

What was the last known trading price?

The stock last traded at $0.02 on Mar 12, 2026 before being delisted.

Procaps Group S.A. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Jose Antonio Toledo Vieira CEO
NASDAQ (NMS) Exchange
L7756P110 CUSIP
LU Country
5,500 Employees
- Last Dividend
30 Sep 2021 Last Split
30 Sep 2021 IPO Date

Overview

Procaps Group S.A. stands as a prominent global entity in the pharmaceutical sector, dedicated to the development, production, and marketing of an extensive range of pharmaceutical solutions. Since its inception in 1977, the company has established a significant footprint worldwide, driven by its commitment to healthcare innovation and excellence. Based in Luxembourg, Luxembourg, Procaps Group S.A. caters to a diverse array of therapeutic needs, signifying a comprehensive approach towards enhancing health and well-being across various populations.

Products and Services

Procaps Group S.A. offers a wide array of products and services across numerous therapeutic areas and healthcare needs:

  • Branded Prescription Drugs: The company formulates, manufactures, and markets a variety of branded prescription drugs, catering to therapeutic areas such as feminine care, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, respiratory health, and more.
  • Hospital Use Drugs: Procaps provides a range of pharmaceutical products designed for hospital use, including antibiotics, blood clot treatments, personal protective equipment, immunosuppressants, oncology drugs, and analgesics.
  • Over-The-Counter (OTC) Consumer Healthcare Products: The company also markets OTC healthcare products in approximately eight therapeutic areas, encompassing gastrointestinal, skin care, cough and cold, analgesics, urological issues, vitamins, minerals, and supplements. These products target various health concerns, including antibiotics, anti-infective, anti-parasitic treatments, cardiovascular health, feminine care, cutaneous antimycotic treatments, pain killers, gastrointestinal health, hormonal treatments, metabolic disorders, endocrine issues, nervous system disorders, ophthalmic concerns, osteoarticular health, respiratory issues, diet supplements, and vitamin and mineral deficiencies.
  • Diabetes Solutions: Procaps extends its healthcare solutions to those managing diabetes, offering products such as blood glucose meters, telemonitoring products, oral anti-diabetics, cosmeceuticals, insulin delivery systems, and other diabetes management tools.
  • Contract Drug Development and Manufacturing: Beyond its direct market offerings, Procaps Group S.A. provides contract drug development and manufacturing services to third-party pharmaceutical companies. The company specializes in soft gelatin capsule technologies, showcasing its advanced capabilities in pharmaceutical manufacturing.

Contact Information

Address: 9 rue de Bitbourg
Phone: 356 7995 6138